Cyltezo-Phase III -in Psoriasis

Biosimilar Cyltezo ® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasisData show that Cyltezo © (adalimumab- adbm) and Humira®* have similar efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis1At week 16, the study met the primary endpoint, demonstrating clinical equivalence to Humira ®1Data will be presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news

Related Links:

ConclusionsThe elevated burden of HZ in Japanese individuals harboring IC conditions and chronic disorders documented in our study underlines the need for prevention of HZ in people with these conditions.FundingGlaxoSmithKline Biologicals SA.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
People with psoriasis may be at increased risk of sexual dysfunction, particularly when they also suffer from mood disorders or arthritis, a research review suggests.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L Abstract The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such as psoriasis, alopecia areata, atopic dermatitis and vitilig...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
CONCLUSION: The aim of this review, other than providing a summarized update on the clinical knowledge on this special topic, is also to raise awareness for the need to conduct larger systematic studies in order to adequately evaluate the use of biologics in these special patient categories and therefore draw definite conclusions on their safety profile. PMID: 30428753 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Authors: Diotallevi F, Campanati A, Radi G, Molinelli E, Offidani A Abstract BACKGROUND: Data concerning clinical experience in real world setting with ixekizumab for psoriasis are still exiguous and aim of this report is to provide our experience in the use of ixekizumab in out-patient setting. METHODS: Fifteen Caucasian individuals (10 male, 5 females; mean age 58.1; range 30-75 years) affected by moderate to severe plaque psoriasis (PASI≥10 e/o DLQI≥10 e/O BSA≥10) were treated with Ixekizumab, following dosing regimen of technical data sheet and clinically evaluated both after 4 weeks (T4) and 12 we...
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
Publication date: Available online 15 November 2018Source: International Journal of PharmaceuticsAuthor(s): Prerana Carter, Balaji Narasimhan, Qun WangAbstractTransdermal drug delivery (TDDS) has been highly explored in the past couple of decades due to benefits such as increased patient compliance, improved drug release, tissue targeting, avoiding the presystemic metabolism in the liver etc. However, the stratum corneum poses as the rate limiting barrier to the permeation of drugs through the skin, which has been a continuous challenge in TDDS. This review covers the various types of nanoparticles and nanoemulsions that a...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conclusions: The changes in expression profiles of TGF-β1-3 and TGF-βRI-III during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine. PMID: 30429710 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Conclusions: YKL-40 can be a useful biomarker for both diagnosing and monitoring joint involvement in psoriatic patients. PMID: 30429706 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
ConclusionsThe diagnosis of GT is mainly clinical. GT is an asymptomatic disorder that usually requires no treatment. Understanding GT is necessary due to the comorbid intraoral and extraoral diseases that accompany the condition.ResumenIntroducciónLa lengua geográfica (LG) es una lesión de origen desconocido asociada a enfermedades sistémicas, por lo que su atención plantea una validez multidisciplinar.MétodosLa búsqueda de los artículos fue realizada a partir de las bases de datos de PubMed, Embase, Web of Science y Cochrane Database. Los criterios de selecció...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
More News: Dermatology | Humira | Psoriasis | Research | Skin | Study